Generic name · Bone Health / RANKL
Denosumab J-Code / HCPCS Code
In short
Denosumab is billed under HCPCS J0897 — Injection, denosumab, 1 mg. One billing unit is 1 mg.
Denosumab biosimilars have their own HCPCS codes.
Reference
- Code
- J0897 — Injection, denosumab, 1 mgMed-Code curated
- Billing unit
- 1 mg
- Pharmacologic class
- RANK Ligand InhibitorFrom the FDA listings below
- Labelers
- Accord BioPharma Inc.; Amgen, Inc; Amneal Pharmaceuticals LLC; Biocon Biologics Inc.; CELLTRION USA, Inc.; Cordavis Limited; Fresenius Kabi USA, LLC; Hikma Pharmaceuticals USA Inc.and 2 more
- J-code category
- Bone Health / RANKL
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Aukelsodenosumab-kyqq | Denosumab 120 mg/1.7mL | InjectionSubcutaneous | Biocon Biologics Inc. | 83257-030 |
| Bildyosdenosumab | Denosumab 60 mg/mL | Injection, SolutionSubcutaneous | Organon LLC | 78206-193 |
| Bilprevdadenosumab | Denosumab 120 mg/1.7mL | Injection, SolutionSubcutaneous | Organon LLC | 78206-195 |
| Bomyntradenosumab | Denosumab 70 mg/mL | InjectionSubcutaneous | Fresenius Kabi USA, LLC | 65219-670 |
| Bomyntradenosumab | Denosumab 70 mg/mL | InjectionSubcutaneous | Fresenius Kabi USA, LLC | 65219-672 |
| Boncresadenosumab-mobz | Denosumab 60 mg/mL | Injection, SolutionSubcutaneous | Amneal Pharmaceuticals LLC | 70121-2702 |
| Bosayadenosumab-kyqq | Denosumab 60 mg/mL | InjectionSubcutaneous | Biocon Biologics Inc. | 83257-029 |
| Conexxencedenosumab | Denosumab 60 mg/mL | InjectionSubcutaneous | Fresenius Kabi USA, LLC | 65219-668 |
| Denosumab-BMWO | Denosumab 60 mg/mL | InjectionSubcutaneous | CELLTRION USA, Inc. | 72606-058 |
| Denosumab-BMWO | Denosumab 120 mg/1.7mL | InjectionSubcutaneous | CELLTRION USA, Inc. | 72606-059 |
| Enobydenosumab-qbde | Denosumab 60 mg/mL | InjectionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 0143-9165 |
| Jubbontidenosumab | Denosumab 60 mg/mL | InjectionSubcutaneous | Sandoz Inc | 61314-240 |
| Jubereqdenosumab-desu | Denosumab 70 mg/mL | InjectionSubcutaneous | Accord BioPharma Inc. | 69448-022 |
| Osenveltdenosumab-bmwo | Denosumab 120 mg/1.7mL | InjectionSubcutaneous | CELLTRION USA, Inc. | 72606-038 |
| Ospomyvdenosumab | Denosumab 60 mg/mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-012 |
| Osvyrtidenosumab-desu | Denosumab 60 mg/mL | InjectionSubcutaneous | Accord BioPharma Inc. | 69448-021 |
| Oziltusdenosumab-mobz | Denosumab 70 mg/mL | Injection, SolutionSubcutaneous | Amneal Pharmaceuticals LLC | 70121-2701 |
| Proliadenosumab | Denosumab 60 mg/mL | InjectionSubcutaneous | Amgen, Inc | 55513-710 |
| Stoboclodenosumab-bmwo | Denosumab 60 mg/mL | InjectionSubcutaneous | CELLTRION USA, Inc. | 72606-037 |
| Wyostdenosumab | Denosumab 120 mg/1.7mL | InjectionSubcutaneous | Sandoz Inc | 61314-228 |
| Xgevadenosumab | Denosumab 120 mg/1.7mL | InjectionSubcutaneous | Amgen, Inc | 55513-730 |
| Xtrenbodenosumab-qbde | Denosumab 120 mg/1.7mL | InjectionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 0143-9166 |
NDCs billed under J0897
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 4 NDCs to J0897 for Prolia and Xgeva. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Prolia | 55513-0710-01 | Amgen Inc | 1 | 60 |
| Prolia | 55513-0710-21 | Amgen Inc | 1 | 60 |
| Xgeva | 55513-0730-01 | Amgen Inc | 1 | 120 |
| Xgeva | 55513-0730-21 | Amgen Inc | 1.7 | 120 |